WHAT IS CLAIMED IS:

1. A compound of the formula I:



I

wherein:

R^1 is selected from the group consisting of:

(1) hydrogen,

(2) C_{1-6}alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl,

(3) C_{3-7}cycloalkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and

(4) phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:

(a) -C_{1-6}alkyl,

(b) -O-C_{1-6}alkyl,

(c) halo,

(d) hydroxy,

(e) trifluoromethyl,

(f) -OCF_3,

(g) -CO_2R^9,

wherein R^9 is independently selected from:

(i) hydrogen,

(ii) -C_{1-6}alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(iii) benzyl, and

(iv) phenyl,

(h) -$NR^{10}R^{11}$,

wherein R^{10} and R^{11} are independently selected from:

(i) hydrogen,

(ii) -C_{1-6}alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(iii) -C_{5-6}cycloalkyl,

(iv) benzyl,
(v) phenyl,
(vi) -S(O)2-C1-6alkyl,
(vii) -S(O)2-benzyl, and
(viii) -S(O)2-phenyl,
(i) -CONR10R11, and
(j) -NO2;

(5) heterocycle, wherein heterocycle is selected from: benzoimidazolyl, benzimidazolonyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyridin-2-onyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof, which is unsubstituted or substituted with one or more substituents independently selected from:
(a) -C1-6alkyl,
(b) -O-C1-6alkyl,
(c) halo,
(d) hydroxy,
(e) phenyl,
(f) trifluoromethyl,
(g) -OCF3,
(h) -CO2R9,

(i) $-NR^{10}R^{11}$, and
(j) $-CONR^{10}R^{11}$;

R^2 and R^5 are independently selected from the group consisting of:

(1) hydrogen,
(2) C_{1-6}alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl,
(3) C_{3-7}cycloalkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and
(4) phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:
  (a) $-C_{1-6}$alkyl, which is unsubstituted or substituted with $-NR^{10}R^{11}$,
  (b) $-O-C_{1-6}$alkyl,
  (c) halo,
  (d) hydroxy,
  (e) trifluoromethyl,
  (f) $-OCF_3$;
  (g) $-CO_2R^9$,
  (h) $-NR^{10}R^{11}$,
  (i) $-C(O)NR^{10}R^{11}$, and
  (j) $-NO_2$,
(5) heterocycle, wherein heterocycle is selected from:
benzoimidazolyl, benzimidazolonyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyridin-2-onyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl,

dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof, which is unsubstituted or substituted with one or more substituents independently selected from:

(a) -C_{1-6}alkyl,
(b) -O-C_{1-6}alkyl,
(c) halo,
(d) hydroxy,
(e) phenyl,
(f) trifluoromethyl,
(g) -OCF_3;
(h) -CO_2R^9,
(i) -$NR^{10}R^{11}$, and
(j) -$CONR^{10}R^{11}$;

R^3 is independently selected from the group consisting of:

(1) hydrogen, and
(2) C_{1-6}alkyl;

R^4 is selected from the group consisting of:

(1) C_{1-6}alkyl, which is unsubstituted or substituted with halogen, hydroxyl, phenyl or heterocycle,
(2) C_{3-7}cycloalkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and
(3) phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:
(a) -C_{1-6}alkyl,
(b) -O-C_{1-6}alkyl,
(c) halo,
(d) hydroxy,
(e) trifluoromethyl,
(f) -OCF_3,

(g) $-CO_2R^9$,
(h) -CN,
(i) $-NR^{10}R^{11}$,
(j) $-CONR^{10}R^{11}$, and
(k) $-NO_2$;

(4) heterocycle, wherein heterocycle is selected from: benzoimidazolyl, benzimidazolonyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyridin-2-onyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof, which is unsubstituted or substituted with one or more substituents independently selected from:
(a) $-C_{1-6}$alkyl,
(b) $-O-C_{1-6}$alkyl,
(c) halo,
(d) hydroxy,
(e) phenyl,
(f) trifluoromethyl,
(g) $-OCF_3$,
(h) $-CO_2R^9$,
(i) $-NR^{10}R^{11}$, and
(j) $-CONR^{10}R^{11}$;

and pharmaceutically acceptable salts thereof and individual diastereomers thereof.

2. The compound of Claim 1 of the formula Ia:



Ia

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

3. The compound of Claim 1 of the formula Ib:



Ib

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

4. The compound of Claim 1 of the formula Ic:



Ic

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

5. The compound of Claim 1 wherein R^1 is hydrogen.

6. The compound of Claim 1 wherein R^1 is phenyl.

7. The compound of Claim 1 wherein R^2 is phenyl.

8. The compound of Claim 1 wherein R^3 is hydrogen.

9. The compound of Claim 1 wherein R^4 is phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:

(a) -C_{1-6}alkyl,
(b) -O-C_{1-6}alkyl,
(c) halo,
(d) hydroxy,
(e) trifluoromethyl,
(f) -OCF_3;
(g) -CO_2-C_{1-6}alkyl,
(h) -CN,
(i) -NH_2,
(j) -NH-C_{1-6}alkyl,
(k) -$CONH_2$, and
(l) -CONH-C_{1-6}alkyl.

10. The compound of Claim 9 wherein R^4 is phenyl, which is unsubstituted or substituted with halo or -CN.

11. The compound of Claim 10 wherein R^4 is phenyl.

12. The compound of Claim 1 wherein R^4 is pyridyl.

13. The compound of Claim 1 wherein R^5 is hydrogen.

14. A compound which is selected from the group consisting of:











I































and pharmaceutically acceptable salts thereof.

15. A pharmaceutical composition which comprises an inert carrier and a compound of Claim 1.

16. A method for potentiation or inhibition of metabotropic glutamate receptor activity in a mammal which comprises the administration of an effective amount of the compound of Claim 1.

17. A method for the manufacture of a medicament for potentiation or inhibition of metabotorpic glutamate receptor activity in a mammal comprising combining the compound of Claim 1 with a pharmaceutical carrier or diluent.

18. A method for treating a neurological and psychiatric disorders associated with glutamate dysfunction in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1.

19. A method for treating schizophrenia in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1.

20. A method for treating anxiety in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1.